IRIS
DELLA PORTA, MATTEO GIOVANNI
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.004
AS - Asia 3.848
EU - Europa 2.826
SA - Sud America 489
Continente sconosciuto - Info sul continente non disponibili 204
AF - Africa 117
OC - Oceania 10
Totale 12.498
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.880
CN - Cina 2.017
SG - Singapore 742
IE - Irlanda 596
HK - Hong Kong 427
UA - Ucraina 415
BR - Brasile 388
FI - Finlandia 385
VN - Vietnam 333
DE - Germania 288
RU - Federazione Russa 259
IT - Italia 242
FR - Francia 175
SE - Svezia 169
GB - Regno Unito 163
IN - India 67
CA - Canada 62
MX - Messico 38
BD - Bangladesh 36
ZA - Sudafrica 35
AR - Argentina 32
JP - Giappone 29
IQ - Iraq 26
TR - Turchia 25
NL - Olanda 21
PL - Polonia 21
CO - Colombia 20
EC - Ecuador 17
PK - Pakistan 17
BE - Belgio 16
ID - Indonesia 16
SA - Arabia Saudita 15
AT - Austria 14
ES - Italia 14
KE - Kenya 13
UZ - Uzbekistan 13
TN - Tunisia 12
CZ - Repubblica Ceca 11
EU - Europa 10
MU - Mauritius 10
AU - Australia 9
MA - Marocco 9
PH - Filippine 9
NP - Nepal 8
AZ - Azerbaigian 7
CR - Costa Rica 7
JO - Giordania 7
KZ - Kazakistan 7
LT - Lituania 7
RO - Romania 7
BO - Bolivia 6
CL - Cile 6
EG - Egitto 6
ET - Etiopia 6
IL - Israele 6
MY - Malesia 6
PY - Paraguay 6
UY - Uruguay 5
VE - Venezuela 5
AE - Emirati Arabi Uniti 4
CH - Svizzera 4
NG - Nigeria 4
OM - Oman 4
PA - Panama 4
PE - Perù 4
XK - ???statistics.table.value.countryCode.XK??? 4
AM - Armenia 3
BG - Bulgaria 3
DZ - Algeria 3
GE - Georgia 3
HU - Ungheria 3
JM - Giamaica 3
LA - Repubblica Popolare Democratica del Laos 3
LB - Libano 3
PT - Portogallo 3
SK - Slovacchia (Repubblica Slovacca) 3
AO - Angola 2
BW - Botswana 2
DK - Danimarca 2
DO - Repubblica Dominicana 2
GH - Ghana 2
GR - Grecia 2
HN - Honduras 2
KR - Corea 2
KW - Kuwait 2
MN - Mongolia 2
NI - Nicaragua 2
SN - Senegal 2
SV - El Salvador 2
BF - Burkina Faso 1
BH - Bahrain 1
CG - Congo 1
CI - Costa d'Avorio 1
CM - Camerun 1
CU - Cuba 1
CV - Capo Verde 1
CW - ???statistics.table.value.countryCode.CW??? 1
CY - Cipro 1
GA - Gabon 1
GN - Guinea 1
Totale 12.293
Salva come PNG Salva come JPEG
Città #
Chandler 692
Dublin 596
San Jose 596
Jacksonville 522
Nanjing 459
Hong Kong 422
Ashburn 392
Singapore 361
Beijing 288
Dallas 234
Boardman 222
Nanchang 176
Princeton 136
Lawrence 131
Changsha 129
Council Bluffs 128
Wilmington 128
Hebei 116
Lauterbourg 116
Medford 109
Shenyang 107
Los Angeles 103
Helsinki 102
Ho Chi Minh City 102
New York 93
Jiaxing 92
Hanoi 90
Tianjin 78
Buffalo 68
Hangzhou 68
Ann Arbor 67
Milan 54
Shanghai 50
Santa Clara 46
Moscow 45
Pavia 44
Munich 38
Toronto 37
Redondo Beach 33
São Paulo 31
Woodbridge 31
Tokyo 27
Turku 26
Norwalk 25
Johannesburg 23
Da Nang 21
San Francisco 21
Warsaw 21
Chennai 20
The Dalles 20
Guangzhou 19
Orem 19
Frankfurt am Main 18
Brooklyn 17
Falls Church 17
Seattle 17
Brussels 16
Haiphong 16
Verona 16
Belo Horizonte 15
London 15
Poplar 15
Kunming 14
Washington 14
Des Moines 13
Jinan 13
Mexico City 13
Boston 12
Nairobi 12
Rome 12
Stockholm 12
Zhengzhou 12
Chicago 11
Denver 11
Houston 11
Hải Dương 11
Dearborn 10
Fairfield 10
Montreal 10
Nuremberg 10
Tashkent 10
Atlanta 9
Dhaka 9
Taizhou 9
Vienna 9
Ankara 8
Baghdad 8
Brasília 8
Columbus 8
Ningbo 8
Baku 7
Falkenstein 7
Fuzhou 7
Istanbul 7
Rio de Janeiro 7
Amman 6
Bogotá 6
Clifton 6
Guarulhos 6
Lanzhou 6
Totale 8.098
Salva come PNG Salva come JPEG
Nome #
Clinical effects of driver somatic mutations on the outcomes of patients with myelodysplastic syndromes treated with allogeneic hematopoietic stem-cell transplantation. 169
Alterata espressione dei canali del Ca2+ in cellule progenitrici endoteliali di pazienti affetti da carcinoma cellulare renale, mielofibrosi idiopatica e tumore della mammella 158
A rule-based expert system for automatic implementation of somatic variant clinical interpretation guidelines 152
ANALYSIS OF THE MITOCHONDRIAL FERRITIN PHYSIOPATHOLOGICAL ROLE IN SIDEROBLASTIC ERYTHROPOIESIS 151
Clinical relevance of bone marrow fibrosis and CD34-positive cell clusters in primary myelodysplastic syndrome 146
A WHO classification-based prognostic scoring system (WPSS) for predicting survival in myelodysplastic syndromes 145
Chronic lymphocytic leukemia with 6q- shows distinct hematological features and intermediate prognosis. 144
A prognostic model for predicting the impact of comorbidities on survival of patients with myelodysplastic syndromes 144
Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts 136
27P * Common gene signature expressed by breast and kidney cancers-derived endothelial colony forming cells 135
An unusual clinical presentation of multiple myeloma with involvement of the oro-pharynx. 134
Circulating endothelial cell separation from peripheral blood of patients affected by myelodysplastic syndromes: Preliminary results obtained by a new immunomagnetic procedure 132
Clinical significance of neutrophil CD177 mRNA expression in Ph-negative chronic myeloproliferative disorders 131
Biological and clinical relevance of matrix metalloproteinases 2 and 9 in acute myeloid leukaemias and myelodysplastic syndromes. 130
Classification and prognostic evaluation of myelodysplastic syndromes 128
Burkitt-like lymphoma infiltrating a hyperfunctioning thyroid adenoma and presenting as a hot nodule. 124
CD34 and CD2 expression in acute promyelocytic leukemia. 122
Complex Patterns of Chromosome 11 Aberrations in Myeloid Malignancies Target CBL, MLL, DDB1 and LMO2. 121
WHO classification and WPSS predict posttransplantation outcome in patients with myelodysplastic syndrome: a study from the Gruppo Italiano Trapianto di Midollo Osseo (GITMO). 116
Over-expression of mitochondrial ferritin affects the JAK2/STAT5 pathway in K562 cells and causes mitochondrial iron accumulation. 115
Ultrastructural and functional differences between normal and tumor endothelial progenitor cells 114
CHARACTERIZATION OF A CELLULAR MODEL FOR THE STUDY OF MITOCHONDRIAL FERRITIN PHYSIOPATHOLOGICAL ROLE IN SIDEROBLASTIC ERYTHROPOIESIS 114
Clinical importance of interphase cytogenetics detecting occult chromosome lesions in myelodysplastic syndromes with normal karyotype. 113
Consolidation treatment with autologous peripheral blood progenitor cell transplantation in acute myeloid leukemia: a single center experience. 113
Clinical and biological implications of driver mutations in myelodysplastic syndromes 112
Diagnostic utility of flow cytometry in low-grade myelodysplastic syndromes: a prospective validation study. 111
Dendritic cells and vascular endothelial growth factor in colorectal cancer: correlations with clinicobiological findings. 111
Familial chronic myeloproliferative disorders: clinical phenotype and evidence of disease anticipation 110
Clinical evaluation of extra-hematological comorbidity in myelodysplastic syndromes: "ready-to-wear" versus "made-to-measure" tools. 110
CD34+ and endothelial progenitor cells in patients with various degrees of congestive heart failure. 109
Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes 108
Should cytoreductive treatment be performed before transplantation in patients with high-risk myelodysplastic syndrome? 108
Consolidation treatment with autologous peripheral blood progenitor cell transplantation in acute myeloid leukemia 108
Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms 108
Prognosis of secondary acute myeloid leukemia 107
Survivin expression, apoptosis and proliferation in chronic myelomonocytic leukemia 105
Correlation of the FLIPI score for follicular lymphoma with period of diagnosis and type of treatment 105
Erythropoietin and granulocyte-colony stimulating factor treatment associated with improved survival in myelodysplastic syndrome. 104
Morphological features and prognostic implication in a retrospective analysis of 370 patients with myelodysplastic syndrome 104
Dendritic cell recovery after allogeneic stem-cell transplantation in acute leukemia: correlations with clinical and transplant characteristics. 103
Gene expression profiling of CD34+ cells in patients with the 5q- syndrome 101
Driver somatic mutations identify distinct disease entities within myeloid neoplasms with myelodysplasia. 101
PRV-1 and its correlation with treatments and disease status in 210 patients with polycythemia vera and essential thrombocythemia 100
Marked down-regulation of nucleophosmin-1 is associated with advanced del(5q) myelodysplastic syndrome 100
VASCULAR ENDOTHELIAL GROWTH FACTOR OVEREXPRESSION IN BONE MARROW CELLS FROM PATIENTS WITH MYELODYSPLASTIC SYNDROME: BIOLOGICAL AND CLINICAL RELEVANCE 100
Effects of mitochondrial ferritin overexpression in normal and sideroblastic erythroid progenitors. 100
Clinical relevance of anemia and transfusion iron overload in myelodysplastic syndromes 99
Role of the molecular staging and response in the management of follicular lymphoma patients 99
Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: Results from the large 1-year EPIC study. 97
Revisiting guidelines for integration of flow cytometry results in the WHO classification of myelodysplastic syndromes-proposal from the International/European LeukemiaNet Working Group for Flow Cytometry in MDS. 96
SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts 96
Flow cytometry immunophenotyping for the evaluation of bone marrow dysplasia. 95
Predicting survival and leukemic evolution in patients with myelodysplastic syndrome 95
Treatment of anemia with erythroid stimulating agents in myelodysplastic syndromes. 95
Identification of gene expression-based prognostic markers in the hematopoietic stem cells of patients with myelodysplastic syndromes 94
Prevalence, incidence and types of mild anemia in the elderly: the "Health and Anemia" population-based study. 92
JAK2 (V617F) as an acquired somatic mutation and a secondary genetic event associated with disease progression in familial myeloproliferative disorders 92
Remodelling of the Ca2+ signalling machinery in endothelial progenitor cells isolated from breast cancer patients 92
Haploinsufficiency of RPS14 in 5q− syndrome is associated with deregulation of ribosomal- and translation-related genes 91
In patients with myelodysplastic syndromes response to rHuEPO and G-CSF treatment is related to an increase of cytogenetically normal CD34 cells. 91
Predictive factors for the outcome of allogeneic transplantation in patients with MDS stratified according to the revised IPSS-R. 91
A Randomized Double-Blind Placebo-Controlled Clinical Study to Evaluate the Effect on the Weight of a Medical Device with Polyglucosamine L112 in a Group of Overweight and Obese Subjects 90
Hematologic responses with deferasirox therapy in transfusion-dependent myelodysplastic syndromes patients. 90
Myelodysplastic syndromes and bone marrow microenvironment. 90
Pretransplantation therapy with hypomethylating agents in patients with myelodysplastic syndromes receiving reduced-intensity conditioning regimens. 90
Inappropriately low hepcidin levels in patients with myelodysplastic syndrome carrying a somatic mutation of SF3B1 90
Molecular and clinical features of refractory anemia with ringed sideroblasts associated with marked thrombocytosis. 90
Marked downregulation of the granulopoiesis regulator LEF1 is associated with disease progression in the myelodysplastic syndromes. 89
THE IMPACT OF THE DEGREE OF ANEMIA ON SURVIVAL OF PATIENTS WITH MYELODYSPLASTIC SYNDROME. A BASIS FOR PROGNOSTIC ASSESSMENT AND CLINICAL DECISION MAKING 89
Methylenetetrahydrofolate reductase C677T and A1298C gene variants in adult non-Hodgkin's lymphoma patients: association with toxicity and survival 89
Prognostic impact of pre-transplantation transfusion history and secondary iron overload in patients with myelodysplastic syndrome undergoing allogeneic stem cell transplantation: a GITMO study. 88
Deregulated gene expression pathways in myelodysplastic syndrome hematopoietic stem cells. 88
Minimal morphological criteria for defining bone marrow dysplasia: a basis for clinical implementation of WHO classification of myelodysplastic syndromes 88
Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-yr prospective study 87
Validation of WHO classification-based Prognostic Scoring System (WPSS) for myelodysplastic syndromes and comparison with the revised International Prognostic Scoring System (IPSS-R). A study of the International Working Group for Prognosis in Myelodysplasia (IWG-PM) 87
Splenectomy for treatment of immune thrombocytopenic purpura. 86
Dendritic cells in acute promyelocytic leukaemia. 86
Gene polymorphisms in folate metabolizing enzymes in adult acute lymphoblastic leukemia: effects on methotrexate-related toxicity and survival. 86
Myelodysplastic syndromes with bone marrow fibrosis. 86
Improving the prognostic assessment of myelodysplastic syndromes by understanding the biology of the disease 86
Rationale for the clinical application of flow cytometry in patients with myelodysplastic syndromes: position paper of an International Consortium and the European LeukemiaNet Working Group 86
The role of the iron transporter ABCB7 in refractory anemia with ring sideroblasts. 86
Simian virus 40 and lymphoproliferative disorder. 85
rHuEpo administration in patients with low-risk myelodysplastic syndromes: evaluation of erythroid precursors' response by fluorescence in situ hybridization on May-Grunwald-Giemsa-stained bone marrow samples. 83
The genetic basis of myelodysplasia and its clinical relevance 83
Development and validation of a prognostic scoring system for patients with chronic myelomonocytic leukemia 83
Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet 83
DHFR 19-bp insertion/deletion polymorphism and MTHFR C677T in adult acute lymphoblastic leukaemia: is the risk reduction due to intracellular folate unbalancing? 83
Soluble urokinase-type plasminogen activator receptor (suPAR) as an independent factor predicting worse prognosis and extra-bone marrow involvement in multiple myeloma patients. 82
Lymphocyte subpopulation and dendritic cell phenotyping during antineoplastic therapy in human solid tumors. 82
Flow cytometric analysis of peripheral blood dendritic cells in patients with severe sepsis. 82
Risk factors for Gram-negative infections in neutropenic patients. 82
Multilineage involvement in the 5q- syndrome: a fluorescent in situ hybridization study on bone marrow smears. 81
Flow cytometric detection of accelerated telomere shortening in myelodysplastic syndromes: correlations with aetiological and clinical-biological findings. 81
Frequent mutation of the polycomb-associated gene ASXL1 in the myelodysplastic syndromes and in acute myeloid leukemia. 81
From cancer patients to cancer survivors: the issue of Cardioncology--a biological perspective. 81
Optimal timing of allogeneic hematopoietic stem cell transplantation in patients with myelodysplastic syndrome 79
Flow cytometry evaluation of erythroid dysplasia in patients with myelodysplastic syndrome. 78
High resolution melting for the identification of mutations in the iron responsive element of the ferritin light chain gene. 78
Outcome after allogeneic bone marrow transplantation in cytogenetic high-risk myelodysplastic syndromes and acute myeloid leukemia. 78
Totale 10.239
Salva come PNG Salva come JPEG
Categoria #
all - tutte 54.747
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 54.747
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022642 0 0 21 12 36 20 10 30 39 28 85 361
2022/20231.815 178 102 19 194 201 192 2 129 727 13 34 24
2023/2024665 56 182 28 63 53 175 11 24 3 15 21 34
2024/20251.612 61 145 86 39 28 64 47 138 325 60 183 436
2025/20264.060 251 295 424 521 400 150 900 191 343 307 173 105
2026/2027232 78 154 0 0 0 0 0 0 0 0 0 0
Totale 12.498